Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | CARSGEN-B (02171): PROFIT ALERT - ESTIMATED REDUCTION IN LOSS | 1 | HKEx | ||
22.07. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON SATRI-CEL FOR ADJUVANT THERAPY OF PANCREATIC CANCER ACCEPTED FOR POSTER PRESENTATION ... | 2 | HKEx | ||
26.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR SATRICABTAGENE AUTOLEUCEL ... | 2 | HKEx | ||
16.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON CT071 AT 2025 EHA ANNUAL CONGRESS | 3 | HKEx | ||
CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
02.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS ON SATRI-CEL IN THE LANCET AND AT THE 2025 ASCO ANNUAL MEETING | 1 | HKEx | ||
28.05. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SATRICABTAGENE AUTOLEUCEL GRANTED PRIORITY REVIEW BY THE NMPA | 1 | HKEx | ||
22.05. | CARSGEN-B (02171): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2025 | - | HKEx | ||
13.05. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY | 2 | HKEx | ||
12.05. | CARsgen Therapeutics: CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy | 403 | PR Newswire | SHANGHAI, May 11, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
29.04. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON CT071 ACCEPTED FOR POSTER PRESENTATION AT 2025 EHA ANNUAL CONGRESS | 1 | HKEx | ||
16.04. | CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME; AND GRANT OF RSUS PURSUANT TO THE POST-IPO RSU SCHEME | 1 | HKEx | ||
16.04. | CARSGEN-B (02171): LETTER TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
16.04. | CARSGEN-B (02171): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
16.04. | CARSGEN-B (02171): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 2 | HKEx | ||
16.04. | CARSGEN-B (02171): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
16.04. | CARSGEN-B (02171): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR ... | - | HKEx | ||
16.04. | CARSGEN-B (02171): ANNUAL REPORT 2024 | - | HKEx | ||
27.03. | CARsgen's R&D Progress Should Be A Key Watchpoint For Investors | 1 | Benzinga.com | ||
27.03. | CARsgen seeks cell therapy breakthrough but stays in the red for now | 2 | Bamboo Works | ||
19.03. | CARsgen Therapeutics: CARsgen Announced 2024 Annual Results | 496 | PR Newswire | SHANGHAI, March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 44,180 | -0,24 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
EVOTEC | 7,378 | -0,30 % | Aktien KW 30 - Weg erst durch EU-US-Zolleinigung frei? Warten bis zum 1. August? Oder TACO? Bis dahin Einzelwerte im Fokus. News. Evotec. Almonty. Heidelberger Druck. ThyssenKrupp nucera. HELLA. Palfinger. BB Biotech. Sartorius. Berentzen. GFT. STEYR Moto | Aktien: Diese Woche Einzelwerte mit Zahlen im Fokus - Berichtssaison lässt grüssen. Puma bricht ein, Evotec nach unten durchgereicht. Aber auch das: Deutsche Bank zweistelliger Kurssprung. Und so setzte... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 30,060 | -1,12 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 36,880 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,805 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
IMMUNOME | 10,750 | +1,18 % | Immunome Inc. - 8-K, Current Report | ||
BEAM THERAPEUTICS | 20,140 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
ADMA BIOLOGICS | 18,590 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
MOONLAKE IMMUNOTHERAPEUTICS | 50,56 | 0,00 % | ROUNDUP/Aktien New York Schluss: Gewinne - Arbeitsmarktdaten stützen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Dienstag nach einem verhaltenen Start ihre Kursgewinne ausgebaut. Marktbeobachter verwiesen darauf, dass die jüngsten Daten vom US-Arbeitsmarkt trotz... ► Artikel lesen | |
FULCRUM THERAPEUTICS | 6,900 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 | - Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 56,61 | +1,16 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 26,660 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
PTC THERAPEUTICS | 41,800 | +1,46 % | XFRA BH3: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPTC THERAPEUTICS... ► Artikel lesen | |
COGENT BIOSCIENCES | 11,540 | -2,45 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
CG ONCOLOGY | 26,950 | +3,49 % | CG Oncology wins Delaware jury trial against ANI Pharmaceuticals |